Menu
Search Close

Using immunology to fight cancer

Read more

In Phase 1/2 clinical trials for the treatment of patients with metastatic melanoma

Read more

Novel vaccine platform that destroys tumours 

Read more

Cancer Immunotherapy

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £23 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.

Read more

Presentations

Inv€$tival Showcase in association with Jefferies Presentation – 13 Nov 2018

Scancell Investor Presentation, February 16 2018

 

If you wish to see the full unedited version of this presentation please click here

Aim logo

Scancell Holdings PLC is an AIM listed company

Webcasts, Interviews and Media Coverage

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

Mon, 20 May 2019 09:51:00

Scancell surges after announcing milestone in development of its solid tumours treatment

Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research

Mon, 20 May 2019 06:23:00

Scancell adds six ‘world-leading’ cancer specialists to advisory board ahead of Modi-1 trial

“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications”

Fri, 10 May 2019 05:45:00